The investment is expected to boost the manufacturing site's capability and improve Novo Nordisk's capacity to satisfy future demands for the latest medications, including capacity for GLP-1 drugs
Novo Nordisk headquarters, Denmark. (Credit: Novo Nordisk A/S)
Danish pharmaceutical firm Novo Nordisk has invested more than €2.1bn starting this year to expand its current production site in Chartres, France to facilitate the production of current and future product portfolio within serious chronic diseases.
The company’s facility in Chartres was established in 1961 and it produces high-quality treatments for diabetes patients.
The investment is expected to improve Novo Nordisk’s capacity to meet future demands for the latest medications, including capacity for GLP-1 drugs.
It will also boost the manufacturing site’s capability, extend the current Quality Control Laboratory and add aseptic production and final production processes.
Novo Nordisk Production Chartres corporate vice president Charlotte Larsen said: “This significant investment announced today confirms the importance of our French manufacturing site, one of our strategic production sites, as a cornerstone of the growth we are experiencing as a company.
“By maximising the skills and infrastructure we already have on the site, we are expanding our capacity in an efficient way.”
The new facilities are anticipated to double the footprint of the site, the Danish pharmaceutical company said.
In order to handle both present and future processes, the facility will be constructed as a multi-product facility to feature advanced technology and an innovative working environment.
As a financially viable and future-proof facility, the building will concentrate on providing the best quality to patients worldwide in an efficient and environmentally sustainable way.
Novo Nordisk Quality & IT Product Supply EVP Henrik Wulff said: “Our continued investments in our manufacturing sites across the globe demonstrate the belief we have in our current and future product portfolio and its relevance for people living with serious chronic diseases.”
The construction projects are now underway and will be gradually completed between 2026 and 2028.
Upon completion of the building and the facilities are finalised, it is anticipated that the investment will generate more than 500 new employment opportunities to support industrial activities around the clock.
Novo Nordisk said up to 2,000 external workers will be engaged during the construction phase.